Amylin, Boehringer Ingelheim, Eli Lilly endocrine news
The U.S. District Court for the Southern District of California issued a temporary restraining order preventing Eli Lilly from using the same sales force to sell competing diabetes drugs developed under separate partnerships with Amylin and Boehringer Ingelheim. In its order, the court agreed with Amylin that Lilly's January deal with Boehringer would violate Amylin's confidentiality agreement with Lilly. According to the court, by using the same personnel that marketed Amylin's exenatide to market Boehringer's Tradjenta linagliptin, Lilly would be disclosing Amylin's confidential information to a member of the Boehringer deal. A hearing on a preliminary injunction is scheduled for May 31. Amylin filed the suit earlier this month (see BioCentury, May 23).
Lilly said in a statement that Amylin's allegations are "entirely without merit and we fully expect to prevail in this litigation." ...